{
    "Trade/Device Name(s)": [
        "ST AIA-PACK BNP"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K192380",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031038"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "July 14, 2020",
    "Summary Letter Received Date": "July 15, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.1117"
    ],
    "Regulation Name(s)": [
        "B-Type Natriuretic Peptide Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "B-type Natriuretic Peptide (BNP)"
    ],
    "Specimen Type(s)": [
        "Plasma"
    ],
    "Specimen Container(s)": [
        "K2EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Tosoh AIA System Analyzers",
        "AIA-2000",
        "AIA-2000 LA"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoenzymometric assay",
        "Fluorescence detection"
    ],
    "Methodologies": [
        "Two-site immunoenzymometric assay",
        "Sandwich assay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ST AIA-PACK BNP quantitative immunoenzymometric assay for BNP in plasma on Tosoh AIA System Analyzers to aid in heart failure diagnosis",
    "Indications for Use Summary": "For in vitro quantitative measurement of BNP in human (K2EDTA) plasma on Tosoh AIA System Analyzers, as an aid in the diagnosis of heart failure in patients presenting to the emergency department with suspected new onset, acutely decompensated, or exacerbated heart failure",
    "fda_folder": "Clinical Chemistry"
}